March 01, 2023
The Food and Drug Administration’s Blood Products Advisory Committee (BPAC) will meet in open session on April 26 to hear an overview of the research programs in the Division of Hemostasis within the Office of Plasma Protein Therapeutics Chemistry, Manufacturing and Controls. After the open session, the meeting will be closed to the public for committee deliberations.
Interested individuals may present data, information or views, orally or in writing, on issues pending before the committee. Instructions are available in the Federal Register notice. FDA will make background material available to the public no later than two business days before the meeting.